SGH
Sivik Global Healthcare Portfolio holdings
AUM
$224M
This Quarter Return
+3.51%
1 Year Return
+5.3%
3 Year Return
+45.33%
5 Year Return
+103.79%
10 Year Return
+430.94%
AUM
$214M
AUM Growth
+$214M
(-20%)
Cap. Flow
-$56.5M
Cap. Flow
% of AUM
-26.34%
Top 10 Holdings %
Top 10 Hldgs %
32.55%
Holding
81
New
12
Increased
14
Reduced
26
Closed
20
Top Buys
| 1 |
Cardinal Health
CAH
|
$5.01M |
| 2 |
Thermo Fisher Scientific
TMO
|
$4.13M |
| 3 |
Revvity
RVTY
|
$3.41M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
$3.03M |
| 5 |
Bio-Techne
TECH
|
$3.02M |
Top Sells
| 1 |
Cigna
CI
|
$6.09M |
| 2 |
HCA Healthcare
HCA
|
$5.82M |
| 3 |
CELG
Celgene Corp
CELG
|
$5.22M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$4.46M |
| 5 |
Johnson & Johnson
JNJ
|
$4.19M |
Sector Composition
| 1 | Healthcare | 95.03% |
| 2 | Energy | 1.01% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Incyte
INCY
$16.5B
| $3.75M | 1.75% |
45,000
-25,000
| -36% | -$2.08M |
|
|
27
Revvity
RVTY
$10.5B
| $3.41M | 1.59% |
+45,000
| New | +$3.41M |
|
|
ALXN
28
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $3.34M | 1.56% |
30,000
-10,000
| -25% | -$1.11M |
|
29
Zoetis
ZTS
$69.3B
| $3.34M | 1.56% |
40,000
-20,000
| -33% | -$1.67M |
|
|
NVRO
30
DELISTED
NEVRO CORP.
NVRO
| $3.03M | 1.42% |
+35,000
| New | +$3.03M |
|
|
31
Bio-Techne
TECH
$8.5B
| $3.02M | 1.41% |
+20,000
| New | +$3.02M |
|
32
Agilent Technologies
A
$35.7B
| $2.68M | 1.25% |
+40,000
| New | +$2.68M |
|
|
XENT
33
DELISTED
Intersect ENT, Inc
XENT
| $2.56M | 1.19% |
+65,000
| New | +$2.56M |
|
34
Fresenius Medical Care
FMS
$15.1B
| $2.55M | 1.19% |
+50,000
| New | +$2.55M |
|
35
Neurocrine Biosciences
NBIX
$13.8B
| $2.49M | 1.16% |
30,000
-5,000
| -14% | -$415K |
|
|
36
HCA Healthcare
HCA
$94.5B
| $2.43M | 1.13% |
25,000
-60,000
| -71% | -$5.82M |
|
37
Qiagen
QGEN
$10.1B
| $2.42M | 1.13% |
+75,000
| New | +$2.42M |
|
38
McKesson
MCK
$85.4B
| $2.42M | 1.13% |
17,187
-12,813
| -43% | -$1.8M |
|
|
SAGE
39
DELISTED
Sage Therapeutics
SAGE
| $2.42M | 1.13% |
15,000
-5,000
| -25% | -$805K |
|
40
Sarepta Therapeutics
SRPT
$1.78B
| $2.22M | 1.04% |
30,000
| – | – |
|
41
Becton Dickinson
BDX
$55.3B
| $2.17M | 1.01% |
10,000
-7,038
| -41% | -$1.53M |
|
|
LHCG
42
DELISTED
LHC Group LLC
LHCG
| $2.16M | 1.01% |
35,000
-15,000
| -30% | -$924K |
|
43
Bausch Health
BHC
$2.74B
| $2.07M | 0.97% |
130,000
+30,000
| +30% | +$478K |
|
44
Chemed
CHE
$6.67B
| $2.05M | 0.95% |
7,500
-2,500
| -25% | -$682K |
|
|
LOXO
45
DELISTED
Loxo Oncology, Inc
LOXO
| $2.02M | 0.94% |
17,500
| – | – |
|
46
Haemonetics
HAE
$2.63B
| $1.97M | 0.92% |
+26,893
| New | +$1.97M |
|
47
Zimmer Biomet
ZBH
$21B
| $1.94M | 0.91% |
17,797
-27,203
| -60% | -$2.97M |
|
48
Cencora
COR
$56.5B
| $1.94M | 0.91% |
22,500
-37,500
| -63% | -$3.23M |
|
|
AVXS
49
DELISTED
AveXis, Inc. Common Stock
AVXS
| $1.85M | 0.87% |
15,000
-5,000
| -25% | -$618K |
|
|
BPMC
50
DELISTED
Blueprint Medicines
BPMC
| $1.83M | 0.86% |
20,000
| – | – |
|